deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT03066778

A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)

A Phase 3 Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK-3475/SCH900475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subjects With Extensive Stage Small Cell Lung Cancer (KEYNOTE-604)

Sponsor: Merck Sharp & Dohme LLC

Updated 30 times since 2017 Last updated: Sep 2, 2022 Started: May 2, 2017 Primary completion: Dec 2, 2019 Completion: Sep 21, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Small Cell Lung Cancer (SCLC), this trial is completed. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 30 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Mar 2017 – ~Jun 2017 · 3 months · monthly snapshot~Jun 2017 – ~Jul 2017 · 30 days · monthly snapshot~Jul 2017 – ~Aug 2017 · 31 days · monthly snapshot~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Nov 2017 · 31 days · monthly snapshot~Nov 2017 – ~Dec 2017 · 30 days · monthly snapshot~Dec 2017 – ~Jan 2018 · 31 days · monthly snapshot~Jan 2018 – ~Feb 2018 · 31 days · monthly snapshot~Feb 2018 – ~Mar 2018 · 28 days · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Nov 2018 · 3 months · monthly snapshot~Nov 2018 – ~Jan 2019 · 2 months · monthly snapshot~Jan 2019 – ~Mar 2019 · 59 days · monthly snapshot~Mar 2019 – ~Feb 2020 · 11 months · monthly snapshot~Feb 2020 – ~Dec 2020 · 10 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Apr 2021 · 59 days · monthly snapshot~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Jun 2022 · 7 months · monthly snapshot~Jun 2022 – ~Nov 2022 · 5 months · monthly snapshot~Nov 2022 – ~Jul 2024 · 20 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshot~Dec 2025 – present · 7 months · monthly snapshot

Change History

30 versions recorded
  1. Dec 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2025 — Dec 2025 [monthly]

    Completed PHASE3

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  5. Nov 2022 — Jul 2024 [monthly]

    Completed PHASE3

Show 25 earlier versions
  1. Jun 2022 — Nov 2022 [monthly]

    Completed PHASE3

  2. Nov 2021 — Jun 2022 [monthly]

    Completed PHASE3

    Status: Active Not RecruitingCompleted

  3. Sep 2021 — Nov 2021 [monthly]

    Active Not Recruiting PHASE3

  4. Apr 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE3

  5. Feb 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE3

  6. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE3

  7. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  8. Feb 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE3

  9. Mar 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE3

  10. Jan 2019 — Mar 2019 [monthly]

    Active Not Recruiting PHASE3

  11. Nov 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE3

  12. Aug 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE3

    Status: RecruitingActive Not Recruiting

  13. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE3

  14. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE3

  15. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  16. Feb 2018 — Mar 2018 [monthly]

    Recruiting PHASE3

  17. Jan 2018 — Feb 2018 [monthly]

    Recruiting PHASE3

  18. Dec 2017 — Jan 2018 [monthly]

    Recruiting PHASE3

  19. Nov 2017 — Dec 2017 [monthly]

    Recruiting PHASE3

  20. Oct 2017 — Nov 2017 [monthly]

    Recruiting PHASE3

  21. Sep 2017 — Oct 2017 [monthly]

    Recruiting PHASE3

  22. Aug 2017 — Sep 2017 [monthly]

    Recruiting PHASE3

  23. Jul 2017 — Aug 2017 [monthly]

    Recruiting PHASE3

  24. Jun 2017 — Jul 2017 [monthly]

    Recruiting PHASE3

    Status: Not Yet RecruitingRecruiting

  25. Mar 2017 — Jun 2017 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .